Vectura Group (OTCMKTS:VEGPF) versus Oragenics (NYSE:OGEN) Head to Head Review

Institutional and Insider Ownership

18.7% of Oragenics shares are owned by institutional investors. 10.1% of Oragenics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Vectura Group and Oragenics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vectura Group	$244.76 million	4.37	$157.16 million	$0.26	6.81
Oragenics	N/A	N/A	-$20.66 million	($21.42)	-0.06

Vectura Group has higher revenue and earnings than Oragenics. Oragenics is trading at a lower price-to-earnings ratio than Vectura Group, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Vectura Group has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Oragenics has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Profitability

This table compares Vectura Group and Oragenics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vectura Group	N/A	N/A	N/A
Oragenics	N/A	-2,087.95%	-486.56%

Summary

Vectura Group beats Oragenics on 6 of the 9 factors compared between the two stocks.

About Vectura Group

Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.

About Oragenics

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.